WALTHAM, Mass., July 30 -- Summit Technology Inc. reports that its Autonomous Technologies subsidiary has been granted an Investigational Device Exemption by the US Food and Drug Administration. The company will begin studying the feasibility of performing customized ablations using a combination of its patented CustomCornea measurement device and its LADARVision System. The CustomCornea technology was designed to enable surgeons to treat ocular aberrations that cannot be detected or compensated for using existing refractive systems. Summit's study will include the treatment of myopia, hyperopia, and astigmatism through such current methods as photorefractive keratectomy (PRK) and laser in-situ keratomileusis (LASIK).